A comparison of podocyturia, albuminuria and nephrinuria in predicting the development of preeclampsia: A prospective study

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Jim, Belinda ^a   Mehta, Swati ^b   Qipo, Andi ^a   Kim, Kwanghee ^c   Cohen, Hillel W ^a   Moore, Robert M ^a   He, John C ^b,d   Sharma, Shuchita ^d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Providence Alaska Medical Center   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; NEPHRIN; BIOLOGICAL MARKER; MEMBRANE PROTEIN;

ADULT; ALBUMINURIA; ARTICLE; FEMALE; GESTATIONAL AGE; HIGH RISK PREGNANCY; HUMAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; NEPHRINURIA; PODOCYTE; PODOCYTURIA; PREDICTION; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANT WOMAN; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; URINARY TRACT DISEASE; COMPARATIVE STUDY; COMPLICATION; PATHOLOGY; PREGNANCY; RISK; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; URINE;

ADULT; ALBUMINURIA; BIOLOGICAL MARKERS; CREATININE; FEMALE; HUMANS; MEMBRANE PROTEINS; PODOCYTES; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; RISK;

EID: 84904250878     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101445     Document Type: Article

References (23)

1. Duley L (2009) The global impact of pre-eclampsia and eclampsia. Semin Perinatol 33: 130-137.
2. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, et al. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355: 992-1005. (Pubitemid 44343543)
3. Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, et al. (2004) Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 50: 1702-1703. (Pubitemid 39121252)
4. Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, et al. (2003) Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 101: 1266-1274. (Pubitemid 36694354)
5. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, et al. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355: 992-1005. (Pubitemid 44343543)
6. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, et al. (2007) Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50: 137-142. (Pubitemid 46986022)
7. Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, et al. (2007) Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 196: 239 e231-236.
8. Qazi U, Lam C, Karumanchi SA, Petri M (2008) Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol 35: 631-634. (Pubitemid 351500058)
9. Rolfo A, Attini R, Nuzzo AM, Piazzese A, Parisi S, et al. (2013) Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int 83: 177-181.
10. Perni U, Sison C, Sharma V, Helseth G, Hawfield A, et al. (2012) Angiogenic factors in superimposed preeclampsia: a longitudinal study of women with chronic hypertension during pregnancy. Hypertension 59: 740-746.
11. Polsani S, Phipps E, Jim B (2013) Emerging new biomarkers of preeclampsia. Adv Chronic Kidney Dis 20: 271-279.
12. Garovic VD, Wagner SJ, Petrovic LM, Gray CE, Hall P, et al. (2007) Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 22: 1136-1143. (Pubitemid 46523429)
13. Garovic VD, Wagner SJ, Turner ST, Rosenthal DW, Watson WJ, et al. (2007) Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 196: 320 e321-327.
14. Jim B, Jean-Louis P, Qipo A, Garry D, Mian S, et al. (2012) Podocyturia as a Diagnostic Marker for Preeclampsia amongst High-Risk Pregnant Patients. J Pregnancy 2012: 984630.
15. Craici IM, Wagner SJ, Bailey KR, Fitz-Gibbon PD, Wood-Wentz CM, et al. (2013) Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study. Hypertension 61: 1289-1296.
16. Maynard SE, Min JY, Merchan J, Lim KH, Li J, et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658.
17. Camici M (2008) Urinary biomarkers of podocyte injury. Biomark Med 2: 613-616.
18. Kelder TP, Penning ME, Uh HW, Cohen D, Bloemenkamp KW, et al. (2012) Quantitative Polymerase Chain Reaction-Based Analysis of Podocyturia Is a Feasible Diagnostic Tool in Preeclampsia. Hypertension.
19. Aita K, Etoh M, Hamada H, Yokoyama C, Takahashi A, et al. (2009) Acute and transient podocyte loss and proteinuria in preeclampsia. Nephron Clin Pract 112: c65-70.
20. Sakairi T, Abe Y, Kajiyama H, Bartlett LD, Howard LV, et al. (2010) Conditionally immortalized human podocyte cell lines established from urine. Am J Physiol Renal Physiol 298: F557-567.
21. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV (2003) Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 285: F40-48. (Pubitemid 36818460)
22. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, et al. (2000) Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 15: 1379-1383.
23. Rana S, Karumanchi SA, Lindheimer MD (2014) Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension 63: 198-202.